文献速递介入腹部泌尿生殖CT

肾上腺转移瘤经皮冷冻消融:技术可行性与安全性

Percutaneous cryoablation of adrenal metastases: technical feasibility and safety.
PubMed 文献 · Abdom Radiol (NY) · 2021-02-04

回顾性分析2003年4月至2018年10月34例患者共40次肾上腺转移瘤经皮冷冻消融,肿瘤平均3.2 cm、消融区平均5.2 cm,局部复发率10.0%(4/40),随访平均1.8年。肿瘤>3 cm复发率21.0%(4/19)高于≤3 cm的0.0%(0/21)(p=0.027)。主要并发症(≥3级)发生率5.0%(2/40)。结论认为CT引导经皮冷冻消融是安全、有效、低并发症的替代治疗,短暂高血压与残留肾上腺组织相关且可安全处理。

要点

  • 肿瘤>3 cm复发率21.0%(4/19),≤3 cm为0.0%(0/21)(p=0.027)
  • 局部复发率10.0%(4/40),平均随访1.8年
  • 主要并发症(≥3级)发生率5.0%(2/40),其中1例归因于操作

核心结论

  • CT引导经皮冷冻消融是肾上腺转移瘤安全、有效、低并发症的替代治疗选择。
  • 术中短暂高血压仅与残留有活力的肾上腺组织相关,可安全处理并预防性治疗。

研究设计与样本

  • 经IRB批准的回顾性研究,分析2003年4月至2018年10月间的肾上腺转移瘤冷冻消融。
  • 共34例患者、40个肾上腺转移瘤,行40次经皮冷冻消融。
  • 收集组织学、肿瘤大小、消融区大小、大血管邻近程度、局部复发、并发症及麻醉管理下高血压监测资料。
  • 并发症按常见不良事件术语标准(CTCAE)分级。
  • 原文未报告中心数。

诊断标准与关键数值

  • 肿瘤平均大小3.2 cm,消融区平均大小5.2 cm。
  • 局部复发率10.0%(4/40),平均随访1.8年。
  • 肿瘤>3 cm复发率21.0%(4/19),肿瘤≤3 cm复发率0.0%(0/21),p=0.027。
  • 大血管(下腔静脉和主动脉)邻近对复发率无统计学影响(p=0.52),但邻近血管复发者肿瘤>4 cm。
  • 主要并发症(≥3级)发生率5.0%(2/40),其中1例归因于操作。

临床应用与阅片要点

  • 冷冻周期之间被动穿刺阶段或术后复温阶段血压立即升高在残留肾上腺组织患者(21/38)中大于肿瘤完全替代肾上腺者(17/38),p=0.0020。
  • 残留肾上腺组织患者中,术前接受α受体阻滞剂者血压升高幅度较低(p=0.015)。
  • 邻近大血管(下腔静脉和主动脉)未显著影响复发率(p=0.52),但邻近血管复发者肿瘤>4 cm。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To assess the technical feasibility and outcomes of adrenal metastases cryoablation.

MATERIALS AND METHODS: This is an IRB approved retrospective review of adrenal metastases cryoablation between April 2003 and October 2018. Forty percutaneous cryoablation procedures were performed on 40 adrenal metastases in 34 patients. Histology, tumor size, ablation zone size, major vessel proximity, local recurrences, complications, and anesthesia-managed hypertension monitoring was collected. Complications were graded according to the Common Terminology of Complications and Adverse Events (CTCAE).

RESULTS: Mean tumor and ablation size was 3.2 cm and 5.2 cm, respectively. Local recurrence rate was 10.0% (N = 4/40) for a mean follow-up time of 1.8 years. Recurrences for tumors > 3 cm (21.0%, N = 4/19) was greater than for tumors ≤ 3 cm (0.0%, N = 0/21) (p = 0.027). Proximity of major vasculature (i.e., IVC & aorta) did not statistically effect recurrence rates (p = 0.52), however, those that recurred near vasculature were > 4 cm. Major complication (≥ grade 3) rate was 5.0% (N = 2/40), with one major complication attributable to the procedure. Immediate escalation of blood pressure during the passive stick phase (between freeze cycles) or post procedure thaw phase was greater in patients with residual adrenal tissue (N = 21/38) versus masses replacing the entire adrenal gland (N = 17/38), (p = 0.0020). Lower blood pressure elevation was noted in patients with residual adrenal tissue who were pre-treated with alpha blockade (p = 0.015).

CONCLUSIONS: CT-guided percutaneous cryoablation is a safe, effective and low morbidity alternative for patients with adrenal metastases. Transient hypertension is related only to residual viable adrenal tissue but can be safely managed and prophylactically treated.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Aoun HD, Littrup PJ, Nahab B, et al. Percutaneous cryoablation of adrenal metastases: technical feasibility and safety. Abdom Radiol (NY). 2021. PMID: 33543315. doi:10.1007/s00261-020-02848-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。